{
    "nctId": "NCT01100463",
    "briefTitle": "Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome",
    "officialTitle": "A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of 0.1% Uracil Topical Cream (UTC) in the Prevention of Hand-Foot Syndrome (HFS) in Patients With Metastatic Breast Cancer Treated With Capecitabine",
    "overallStatus": "COMPLETED",
    "conditions": "Palmar-Plantar Erythrodysesthesia, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 18,
    "primaryOutcomeMeasure": "Incidence of Grade 2 and 3 HFS as graded by Roche Criteria",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Females, at least 18 years old\n* Histologically or cytologically confirmed metastatic breast cancer\n* You also cannot have any ulcerations or open wounds on palms of hands or soles of feet\n\nExclusion Criteria:\n\n* Patients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C)prior to entering the study or if you have not recovered to Grade 1 or better (except for alopecia)from adverse events due to agents administered more than 2 weeks earlier.\n* Use vitamin 6, chronic use of Cox-2 inhibitors, use full-dose anti- coagulants or use nicotine patches.\n\nThe above is not a complete list of eligibility criteria. Please see your study doctor for more information.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}